Contineum Therapeutics (CTNM) Cash & Equivalents (2023 - 2026)

Contineum Therapeutics' Cash & Equivalents history runs 4 years deep, the most recent figure standing at $20.2 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 10.29% year-over-year to $20.2 million; the TTM figure through Mar 2026 stood at $20.2 million (down 10.29% YoY), while the FY2025 annual figure was $75.6 million, up 244.54% from the prior year.
• Cash & Equivalents was $20.2 million for Q1 2026 at Contineum Therapeutics, down from $75.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $77.2 million in Q2 2024 to a low of $15.5 million in Q4 2023.
• Historically, Cash & Equivalents has averaged $35.4 million across 4 years, with a median of $22.2 million in 2024.
• Biggest YoY gain for Cash & Equivalents was 244.54% in 2025; the steepest drop was 73.09% in 2025.
• A 4-year view of Cash & Equivalents shows it stood at $15.5 million in 2023, then jumped by 41.33% to $21.9 million in 2024, then soared by 244.54% to $75.6 million in 2025, then sank by 73.34% to $20.2 million in 2026.
• The last three Cash & Equivalents figures came in at $20.2 million (Q1 2026), $75.6 million (Q4 2025), and $42.6 million (Q3 2025), per Business Quant data.